Lonza and Cytena combine expertise to allow biotherapeutic manufacturers to benefit from the advantages of Pichia pastoris as an expression system.

We interview Mary Lavin, President of Sartorius North America, about her career.

Epigenetic switches are being used to identify the optimal combination of transcription factors required to derive clinically valuable cell types.

How a new 3D bioprinter could – quite literally – add a new dimension to drug screening and disease modeling.

Andes-based cannabis cultivator Clever Leaves pledges to send US$25 million of leaves to US researchers.

A husband-and-wife-led team used mass spec to identify new drugs that “glue” proteins together. We spoke to Aneika Leney about the project.

Advanz Pharma is fined for substantially hiking the price of a generic drug.

When it comes to conducting clinical trials in emerging geographies, there are four key challenges to consider.

It was by serendipity that Hendrik Dietz learned how to make a virus trap. Now, his team may be sitting on a new way to combat disease.

How can we ease the process of taking ATMPs to clinical trials? Two experts lay out the key considerations.